Venetoclax联合LDAC方案治疗复发难治性急性髓细胞白血病的疗效及对血清VEGF、survivin表达水平的影响 |
| |
引用本文: | 王萍,高红秀,任晓艳,郭力,吴胜胜,陆娟.Venetoclax联合LDAC方案治疗复发难治性急性髓细胞白血病的疗效及对血清VEGF、survivin表达水平的影响[J].实用癌症杂志,2022(2):341-344. |
| |
作者姓名: | 王萍 高红秀 任晓艳 郭力 吴胜胜 陆娟 |
| |
作者单位: | 河南省驻马店市中心医院;河南省南阳市第一人民医院 |
| |
基金项目: | 河南省科技攻关项目(编号:17210230124)。 |
| |
摘 要: | 目的 探究Venetoclax(VEN)联合低剂量阿糖胞苷(LDAC)方案治疗复发难治性急性髓细胞白血病(AML)的疗效及对血清血管内皮生长因子(VEGF)、凋亡存活蛋白(survivin)表达水平影响.方法 选择82例复发难治性AML患者,按照化疗方法不同分为观察组(n=41,VEN+LDAC治疗)和对照组(n=41...
|
关 键 词: | Venetoclax 阿糖胞苷 复发难治性急性髓细胞白血病 血管内皮生长因子 |
Efficacy of Venetoclax Combined with LDAC Regimen in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia and Its Effect on Serum VEGF and Survivin Expression Levels |
| |
Institution: | (Zhumadian Central Hospital,Zhumadian,463000) |
| |
Abstract: | Objective To explore the efficacy of Venetoclax(VEN)combined with low-dose cytarabine(LDAC)regimen in the treatment of relapsed and refractory acute myeloid leukemia(AML)and their impact on serum vascular endothelial growth factor(VEGF)and apoptotic survivin expression levels.Methods 82 patients with relapsed and refractory AML were selected and divided into the observation group(n=41,VEN+LDAC treatment)and the control group(n=41,Placebo+LDAC treatment).Short-term efficacy,adverse reactions,survival time,and serum VEGF and survivin expression levels before and after treatment were assessed in the 2 groups.Results After treatment with a standard chemotherapy regimen,the total remission rate of the observation group was higher than that of the control group(95.12%vs80.49%,P<0.05).The serum VEGF and survivin expression levels of the 2 groups decreased after treatment,and the observation group was lower than the control group(P<0.05).There was no significant difference in the probability of adverse reactions such as hypokalemia,nausea and vomiting,lung infection,leukopenia,and thrombocytopenia between the 2 groups(P>0.05).The 2 groups were followed up for 1 year after treatment,and there was no significant difference in the mortality rate(P>0.05),but the median survival time of the observation group was longer than that of the control group(P<0.05).Conclusion VEN combined with LDAC regimen in the treatment of relapsed and refractory AML can effectively improve the clinical remission rate and prolong survival time,reduce the serum VEGF and survivin levels,and has a low adverse reaction rate.It is a safe and effective treatment method. |
| |
Keywords: | Venetoclax Cytarabine Relapsed and refractory acute myeloid leukemia Vascular endothelial growth factor |
本文献已被 维普 等数据库收录! |
|